Novavax (NASDAQ:) Inc. has reached a settlement with the UK Health Security Agency, agreeing to refund $123.8 million and terminate their existing vaccine supply agreement. The settlement, announced on Monday (NASDAQ:), resolves disputes over the Amended and Restated SARS-COV-2 Vaccine Supply Agreement from July 1, 2022.

The biotechnology company, which specializes in the development of vaccines, entered into a Termination and Settlement Agreement with the UK Authority on November 1, 2024. The agreement not only concludes the ongoing disputes but also releases both parties from any claims related to the original supply contract.

Under the terms of the settlement, Novavax will return the disputed amount in quarterly installments over three years, ending June 30, 2027. This sum includes a provision for interest, although the company has the option to accelerate payments to avoid this additional cost. The first installment is due by November 30, 2024.

This development follows the Authority’s upfront payments to Novavax under the original agreement, which the company is now partially repaying. The specifics of the Settlement Agreement and its amendment will be disclosed in Novavax’s Annual Report on Form 10-K for the fiscal year ending December 31, 2024.

The termination of the Amended and Restated Supply Agreement marks an end to the contractual relationship between Novavax and the UK Authority regarding the vaccine supply. This news is based on a press release statement and provides investors with the latest developments in Novavax’s business dealings.

In other recent news, Novavax has faced a clinical hold on its Phase 2 trial due to a serious adverse event, prompting Jefferies to lower its stock price target to $25 while maintaining a buy rating. BofA Securities also adjusted its price target to $14 in response to the delay, while B.Riley raised its price target to $26, both firms maintaining their respective ratings. Despite the trial hold, Novavax reported Q2 2024 revenue of $415 million, largely due to a strategic partnership with Sanofi (NASDAQ:).

Novavax’s updated Nuvaxovid COVID-19 vaccine has received Marketing Authorization from the European Commission for individuals aged 12 and older. The company is also considering cost reduction strategies, including renegotiating or exiting Advance Purchase Agreements for vaccine distribution and contemplating the sale of its Czech Republic manufacturing facility.

In addition to these developments, Novavax has appointed Ruxandra Draghia-Akli, MD, PhD, as its new Executive Vice President and Head of Research & Development. These are the recent updates for Novavax, a company that continues to navigate through its challenges while maintaining its focus on vaccine development.

InvestingPro Insights

The recent settlement between Novavax and the UK Health Security Agency comes at a challenging time for the company, as reflected in its financial metrics and market performance. According to InvestingPro data, Novavax’s revenue has declined by 38.17% over the last twelve months, with the company reporting a revenue of $987.67 million. This decline aligns with an InvestingPro Tip indicating that analysts anticipate a sales decline in the current year.

Despite these challenges, Novavax’s stock has shown resilience, with a 84.99% price total return over the past six months. However, the company’s short-term performance has been less favorable, with a 32.99% decline in the past month and a 9.43% drop in the last week. These fluctuations are consistent with another InvestingPro Tip noting that the stock’s price movements are quite volatile.

Financially, Novavax is facing profitability issues, with an operating income margin of -28.98% and a negative EBITDA of $240.84 million for the last twelve months. This is reflected in an InvestingPro Tip suggesting that analysts do not anticipate the company will be profitable this year.

For investors seeking a more comprehensive analysis, InvestingPro offers additional insights, with 5 more tips available for Novavax. These additional tips could provide valuable context for understanding the company’s position in light of the recent settlement and its ongoing financial challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.